A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Tizona Therapeutics, Inc
Fate Therapeutics
Eli Lilly and Company
Fate Therapeutics
NKGen Biotech, Inc.
Eli Lilly and Company
Eli Lilly and Company